Agilent closes its Proscia deal, buying into AI-ready digital pathology

Agilent Technologies said on Wednesday, Nov. 4, 2026, that it has completed its acquisition of Proscia, a digital-pathology software company, for $240 million in cash at closing plus up to $30 million in future milestone payments.

Pathology is still a lot of glass slides and microscopes, and the AI tools everyone wants to build need those slides as data first. Agilent already sells pathology instruments and reagents; now it owns the software layer where slides become images and images become AI inputs. $240 million is small for Agilent, but it's a clear bet that the money in pathology is moving from the bench to the screen.

Agilent completed its acquisition of Proscia for $240 million in cash at closing, with up to $30 million more if later performance milestones are met. A milestone payment is cash owed only if a future target is hit. Closing means the sale is finished, not only agreed. Agilent first announced the deal on Oct. 13, 2026. Those figures are Agilent's.

Proscia is now part of Agilent's Life Sciences and Diagnostics Markets Group, the part of the company that sells tools to labs and to the businesses that develop drugs and tests.

Proscia's Concentriq platform is vendor-agnostic digital-pathology software with FDA 510(k) clearance for primary diagnosis. Digital pathology turns a glass microscope slide into a file a pathologist can read on a screen. Vendor-agnostic means the software is not locked to one brand of scanner. Primary diagnosis means a pathologist may use it for the diagnosis itself, not only for a second look. A 510(k) is the FDA clearance for a device judged similar enough to one already allowed. The pathologist still makes the call. Those lines are Agilent's and Proscia's.

Agilent says the deal adds a recurring-revenue software business to its pathology instruments and reagents. Recurring revenue comes in again, as licenses or subscriptions, rather than once, when a machine is sold. Reagents are the chemicals a lab uses up and buys again. Agilent says the software also supports companion-diagnostics development, biopharma drug discovery, and AI-enabled pathology tools. A companion diagnostic is a test that helps decide whether a particular drug fits a particular patient. Those lines are Agilent's.

Proscia says it is used by 16 of the top 20 pharmaceutical companies, and that it was named Global 2026 Best in KLAS for Digital Pathology in Europe. KLAS ranks healthcare software from surveys of the people who use it. That customer count and that ranking are Proscia's, as Agilent's release carries them.

Padraig McDonnell, Agilent's president and chief executive, said: "We're pleased to complete our acquisition of Proscia, further strengthening Agilent's pathology portfolio and establishing a platform for scientific intelligence." He also said: "Together, Agilent and Proscia are well positioned to advance AI-enabled pathology workflows." Those quotations are his.

The picture is Agilent President and CEO Padraig McDonnell, in glasses and a blue suit jacket, smiling with his arms crossed in a bright building atrium. The credit is Agilent Technologies.

In plain terms, Agilent paid $240 million in cash, with up to $30 million more tied to later targets, and Proscia is now inside the company. The software turns pathology slides into images a pathologist can use for a diagnosis, and it works with more than one scanner brand. Agilent already sells the instruments and the chemicals. This is the layer where the slide becomes data.